Amplia Therapeutics |
High $0.08 |
Low $0.07 |
Trades 8 |
Turnover $9,058 |
Volume 120,981 |
| 30 June 2023 at 2:59pm | ||||
|
Market Cap (16-Nov) $46,198,080 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (9-Nov) 30,144 (0.01%) (594th) |
|
52w High $0.275 |
52w Low $0.076 |
P/E - |
EPS -0.02 |
Letter to Shareholders End of Year Summary and 2023 Plans
ATX released this announcement to the ASX on 20 December 2022, 9:08. The announcement is marked as price sensitive, and is 11 page(s) in length and 3.21MB in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.003% short sold according to ASIC data. It was ranked the 634th most shorted stock on the ASX. It is now ranked as the 594th most shorted stock on the ASX with 0.006% of total shares short sold as of the latest reported data (09 November 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| Letter to Shareholders End of Year Summary and 2023 Plans | 20 December 2022, 9:08 |
| Final Director's Interest Notice - Dr. John Lambert | 1 December 2022, 10:10 |
| ACCENT Trial Recruitment Progress | 29 November 2022, 14:15 |
| Appendix 4D and Financial Report Half Year ended 30 Sep 22 | 18 November 2022, 8:19 |
If you were already registered, log in here.